PI3K-alpha (mutant-selective)

Class

Wild-type-sparing, mutant-selective oral PI3K-alpha inhibitor

Pathway

PI3K/AKT/mTOR signaling pathway — selectively inhibits PIK3CA-mutant PI3K-alpha

PI3K-alpha is a lipid-modifying enzyme (a kinase) that sits within the PI3K/AKT/mTOR pathway, a signaling cascade that cells use to translate growth signals from their surface into instructions for growth, survival, and metabolism. In many cancers, the gene encoding this enzyme (PIK3CA) carries activating mutations that lock the pathway in an "on" state, driving uncontrolled proliferation independent of normal upstream cues. Because this same enzyme, in its unmutated (wild-type) form, is essential for normal insulin signaling and glucose regulation throughout the body, inhibitors that block both mutant and wild-type PI3K-alpha tend to cause significant metabolic side effects, particularly elevated blood sugar. A mutant-selective inhibitor is designed to preferentially block the altered, cancer-associated form of the enzyme while largely sparing the normal copy used in healthy tissue. This selectivity is intended to suppress the tumor-driving signal while reducing the systemic metabolic disturbance that has limited earlier, non-selective agents in this class. This mechanism is broadly relevant in solid tumors—most notably certain breast cancers—where PIK3CA mutations are common oncogenic drivers, and the underlying rationale extends to other cancers where this pathway is similarly dysregulated.